Outlook Therapeutics Inc.’s filing revealed that its Chief Operations Officer Dagnon Terry unloaded Company’s shares for reported $0.59 million on Apr 20. In the deal valued at $1.14 per share,520,000 shares were sold. As a result of this transaction, Dagnon Terry now holds 653,058 shares worth roughly $ 0.15 million.
Then, Evanson Jeff sold 267,000 shares, generating $296,370 in total proceeds. Upon selling the shares at $1.11, the Chief Commercial Officer now owns 745,975 shares.
Before that, Evanson Jeff sold 103,255 shares. Outlook Therapeutics Inc. shares valued at $125,971 were divested by the Chief Commercial Officer at a price of $1.22 per share. As a result of the transaction, Evanson Jeff now holds 1,012,975 shares, worth roughly $0.23 million.
H.C. Wainwright downgraded its Outlook Therapeutics Inc. [OTLK] rating to a Neutral from a a Buy in a research note published on Friday, August 31, 2023; the price target was decreased to $1 from $5. PT values the company’s stock at a premium of 77.0 to its Friday closing price.
Price Performance Review of OTLK
On Friday, Outlook Therapeutics Inc. [NASDAQ:OTLK] saw its stock fall -0.83% to $0.23. On the same session, the stock had its day’s lowest price of $0.21, but rose to a high of $0.2333. Over the last five days, the stock has lost -80.51%. Outlook Therapeutics Inc. shares have fallen nearly -79.06% since the year began. Nevertheless, the stocks have fallen -79.81% over the past one year. While a 52-week high of $2.03 was reached on 06/06/23, a 52-week low of $0.21 was recorded on 09/01/23. SMA at 50 days reached $1.5111, while 200 days put it at $1.2577. A total of 20.21 million shares were traded, compared to the trading of 43.16 million shares in the previous session.
Levels Of Support And Resistance For OTLK Stock
The 24-hour chart illustrates a support level at 0.2130, which if violated will result in even more drops to 0.1998. On the upside, there is a resistance level at 0.2363. A further resistance level may holdings at 0.2464. The Relative Strength Index (RSI) on the 14-day chart is 18.83, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.8547, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 98.84%. Stochastics %K at 2.18% indicates the stock is a buying.
How much short interest is there in Outlook Therapeutics Inc.?
A steep rise in short interest was recorded in Outlook Therapeutics Inc. stocks on Aug 14, 2023, growing by 1.1 million shares to a total of 17.51 million shares. Yahoo Finance data shows the prior-month short interest on Jul 13, 2023 was 16.41 million shares. There was a rise of 6.28%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 9.50% of the overall stock float, the days-to-cover ratio (short ratio) rose to 16.19.
Outlook Therapeutics Inc. [OTLK] – Who Are The Largest Shareholders?
In filings from BlackRock Fund Advisors, it is revealed that the company now owns 8,486,890 shares, or roughly 3.31% of the outstanding OTLK shares. In other words, the investor’s shares have risen by 1,071,691 from its previous 13-F filing of 7415199.0. Additionally, The Vanguard Group, Inc. increased 2.14% of its stake after which the total value it holdings stand at $10,112,606, while SSgA Funds Management, Inc. added 36.23% of its stake to hold $4.76 million in the firm. Over the last quarter, Geode Capital Management LLC purchased 183,120 shares of Outlook Therapeutics Inc., while LVW Advisors LLC bought 0 shares. At present, Northern Trust Investments, Inc. is holding 1,255,301 shares valued at $2.17 million. Teachers Advisors LLC owned 521,662 shares of the company at the time of its most recent 13F filing, worth $0.9 million.
According to FactSet, Outlook Therapeutics Inc.’s share price will average $4.75 in the next year, based on opinions of analysts polled by the firm. This is up nearly 1747.83 percent from its previous closing price of $0.23. Analysts expect Outlook Therapeutics Inc. stock to reach the higher price of $10.00, while the lowest price estimate is $1.00. However, 8 analysts have rated OTLK stock as a Hold in their predictions for 2023.